A Phase 3 interventional study of Ixekizumab and Placebo in Psoriasis, Arthritic, sponsored by Eli Lilly and Company. Completed at 116 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-08.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 193 studies in Arthritis, Psoriatic with a site in United States — 29 open to participants now, 59 under way, 20 of them phase 3. Arthritis, Psoriatic · United States.
Among the 193 studies in Arthritis, Psoriatic with a site in United States, this one is the 49th largest by enrollment of the 158 interventional ones that give a count, is one of 4 that started in 2012, is one of 71 in phase 3, and was the 40th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.
Browse Arthritis, Psoriatic studies →29 of the 193 studies in Arthritis, Psoriatic with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–65
Medical College of Wisconsin · Sites in United States
Ages 18+
Takeda · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
193 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 35 · Phase 3 73 · Phase 4 18
First in 1991; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 417 is above the median of 145 across 336 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 237 across the 158 interventional studies, 325 across the 34 observational. Of the 128 that completed or were terminated, 79 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 193 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 8 studies filed under Arthritis, Psoriatic — fewer than ten, so there is no comparison to draw.
16 of the studies in Arthritis, Psoriatic with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641089Phase 3MoonLake Immunotherapeutics AGEvaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | 2027-01-04 |
| NCT06807424Phase 3Janssen Research & Development, LLCA Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis | 2027-02-10 |
| NCT06506916Phase 3UCB Biopharma SRLA Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis | 2027-03-09 |
| NCT06671483Phase 3TakedaA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines | 2027-05-18 |
| NCT06671496Phase 3TakedaA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines | 2027-05-18 |
Add all 16 to your calendar (.ics) → With an account.
Among the 193 studies in Arthritis, Psoriatic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to placebo in participants with active psoriatic arthritis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered by 80 milligram (mg) subcutaneous (SC) injection every 2 weeks (Q2W).
Drug: Ixekizumab
Administered by 80 mg SC injection every 4 weeks (Q4W).
Drug: Ixekizumab
Placebo for ixekizumab and placebo for adalimumab administered by SC injection.
Drug: Placebo
Administered by 40 mg SC injection Q2W.
Drug: Adalimumab
Administered SC
Also known as: LY2439821
Administered SC
Administered SC
Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response at Week 24 (Efficacy of Ixekizumab in Participants With Active Psoriatic Arthritis. Measure: American College of Rheumatology 20 Index [ACR20])
ACR20 response is defined as a ≥20% improvement from baseline for tender joint count (TJC) and swollen joint count (SJC) and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain visual analog scale (VAS), Participant's Global Assessment of Disease Activity VAS (PatGA), Physician's Global Assessment of the Disease Activity VAS (PGA), Participant's Assessment of Physical Function using the Health Assessment Questionnaire Disability Index (HAQ-DI), or Acute Phase Reactant as measured by high sensitivity C-reactive protein (hs-CRP).
Time frame: Week 24
Percentage of Participants Achieving ACR20 Response
ACR20 response is defined as a ≥20% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.
Time frame: Week 12
Percentage of Participants Achieving American College of Rheumatology 50 (ACR50) Response
ACR50 response is defined as a ≥50% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.
Time frame: Week 24
Percentage of Participants Achieving American College of Rheumatology 70 (ACR70) Score
ACR70 response is defined as a ≥70% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.
Time frame: Week 24
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Scores (Quality of Life and Outcome Assessments Measures: Participant Reported Outcomes [PRO])
HAQ-DI is a participant reported questionnaire that measures disease-associated disability (physical function). It consists of 24 questions with 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other daily activities. The disability section scores the participant's self-perception on the degree of difficulty (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do), covering the 8 domains. The HAQ-DI is a composite ranging from 0-3 with lower scores indicating less functional disability. The reported use of special aids or devices and/or the need for assistance of another person to perform these activities is assessed. Least Square (LS) mean was calculated using Mixed Model Repeated Measurements (MMRM) analysis with treatment, baseline score, geographic region, baseline conventional disease modifying anti-rheumatic drugs (cDMARD) experience, visit, and treatment-by-visit interaction.
Time frame: Baseline, Week 24
Change From Baseline in Modified Total Sharp Score (mTSS) (Efficacy of Ixekizumab in Participants With Active Psoriatic Arthritis. Measure: Modified Total Sharp Score [mTSS])
The mTSS measures the extent of bone erosions (20 joints per hand and 12 joints per foot) and joint space narrowing (20 joints per hand and 6 joints per foot), with higher scores representing greater damage. An increase from baseline represents disease progression and / or joint worsening. Scores range from 0-528. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, and baseline cDMARD experience, visit, treatment by visit interaction.
Time frame: Baseline, Week 24
Percentage of Participants Achieving Psoriasis Area and Severity Index 75%, 90%, 100% (PASI 75, 90, 100)
The PASI is an index that combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 were defined as having an improvement of at least 75% in the PASI compared to their baseline measures. Participants achieving PASI 90 were defined as having an improvement of ≥90% in the PASI score compared to baseline. Participants achieving PASI 100 were defined as having an improvement of 100% in the PASI score compared to baseline.
Time frame: Week 12
Change From Baseline in Leeds Enthesitis Index (LEI)
The LEI was developed specifically for use in PsA. It measures enthesitis at 6 sites (lateral epicondyle, left and right; medial femoral condyle, left and right; Achilles tendon insertion, left and right). Each site was assigned a score of 0 (absent) or 1 (present); the results from each site were then added to produce a total score (range 0 to 6). LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, baseline cDMARD experience, visit, treatment by visit interaction.
Time frame: Baseline, Week 12
Change From Baseline in Itching Severity Using the Itch Numeric Rating Scale (NRS) (Quality of Life and Outcome Assessments Measures: Participant Reported Outcomes [PRO])
The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from psoriasis was indicated by circling the number that best described the worst level of itching in the past 24 hours. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, baseline cDMARD experience, visit, and treatment-by-visit interaction.
Time frame: Baseline, Week 12
Change From Baseline in Fatigue Severity NRS Score (Quality of Life and Outcome Assessments Measures: Participant Reported Outcomes [PRO])
The Fatigue Severity NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine." Participants rated their fatigue (feeling tired or worn out) by circling the 1 number that described their worst level of fatigue during the past 24 hours. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, baseline cDMARD experience, visit, and treatment-by-visit interaction.
Time frame: Baseline, Week 24
Change From Baseline in Joint Space Narrowing Score (JSN) And Bone Erosion Score (BES)
JSN score (a component of the modified Total Sharp Score \[mTSS\]) measures the extent of joint space narrowing in peripheral joints. JSN (20 joints per hand and 6 joints per foot), with higher scores representing greater damage. JSN score range is 0 (no narrowing) to 208 (high narrowing). Increase from baseline represents disease progression and / or joint worsening. BES (a component of the \[mTSS\]) measures the extent of bone erosion in peripheral joints. BES measures the extent of joint erosions (20 joints per hand and 12 joints per foot), with higher scores representing greater damage. Erosion score range is from 0 (no erosion) to 320 (high erosion). LS mean was calculated using linear extrapolation for ANCOVA analysis with treatment, baseline score, geographic region, and baseline cDMARD experience.
Time frame: Baseline, Week 24
Change From Baseline in Medical Outcomes Study 36-item Short Form Health Survey (SF-36): Physical Component Summary (PCS) and Mental Component Summary (MCS) (Quality of Life and Outcome Assessments Measures: Participant Reported Outcomes [PRO])
SF-36 is a standardized participant-administered measure designed to evaluate 8 domains of functional health and well being: physical and social functioning, physical and emotional role (role-physical, role-emotional) limitations, bodily pain, general health, vitality, mental health with 2 components (physical component score \[PCS\] and mental component score \[MCS\]). The PCS and MCS scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, baseline cDMARD experience, visit, and treatment-by-visit interaction.
Time frame: Baseline, Week 24
Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Reported 16 Items (QIDS-SR16) (Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes [PRO])
The QIDS-SR16 is a self-administered 16-item instrument intended to assess the existence and severity of symptoms of depression. A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. Each item scaled from 0 (no symptoms) to 3 (all symptoms). The 16 items corresponding to 9 depression domains are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, baseline cDMARD experience, visit, and treatment-by-visit interaction.
Time frame: Baseline, Week 24
Change From Baseline in Disease Activity Score (28 Diarthrodial Joint Count) Based on C-ReactiveProtein (DAS28-CRP) Measure: Non-Arthritic Disease
The DAS28-CRP is a measure of disease activity in 28 joints that consists of a composite numerical score with the following variables: TJC28, SJC28, hs-CRP measured in milligram/liter (mg/L), and Participant's Global Assessment of Disease Activity recorded by participants on a 0 to 100 millimeter (mm) VAS. For DAS28-CRP, the Tender Joint Count 28 (TJC28) and Swollen Joint Count (SJC28) are a subset of TJC and SJC, and include 14 joints on each side of the body: 2 shoulders, 2 elbows, 2 wrists, 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. DAS28 values range from 0 to 9.4. Higher values indicate more severe symptoms and greater functional impairment. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, baseline cDMARD experience, visit, and treatment-by-visit.
Time frame: Baseline, Week 24
Percentage of Participants Meeting the Psoriatic Arthritis Response Criteria (PsARC Modified)
The PsARC is a composite criteria reported in terms of the percentage of participants achieving response according to the following criterion: TJC, SJC, PGA, and PatGA. Overall response is defined by improvement from baseline assessment in 2 of 4 criteria, 1 of which must be a joint count; there must not be worsening in any of the 4 criteria: at least 30% reduction in TJC, at least 30% reduction in SJC, at least a 20 millimeter (mm) reduction in PGA and at least a 20 mm reduction in PatGA which is equivalent to 20 mm reduction. The results from the 2 VAS measures were assessed as a difference from baseline in mm.
Time frame: Week 24
Percentage of Participants Achieving Static Physician Global Assessment (sPGA) of 0 or 1 and With at Least a 2-point Improvement From Baseline
The sPGA is the physician's determination of the severity of the participant's psoriasis lesions overall at a given time point. Overall lesions were categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis was assessed at a given time point on in which 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, 5 = very severe.
Time frame: Week 24
Percent Change From Baseline in Body Surface Area (BSA)
The investigator evaluated the percentage involvement of psoriasis on each participant's BSA on a continuous scale from 0% = no involvement to 100% = full involvement, where 1% corresponded to the size of the participant's handprint including the palm, fingers, and thumb. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, baseline cDMARD experience, visit, and treatment-by-visit interaction.
Time frame: Baseline, Week 24
Change From Baseline in the Nail Psoriasis Severity Index (NAPSI) Score Fingernail Involvement at Baseline
The NAPSI scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps by area of involvement. The fingernail is divided into quadrants. Each fingernail is given a score for fingernail bed Ps 0 (none) to 4 (Ps in 4 quadrants of the fingernail) and fingernail matrix Ps 0 (none) to 4 (Ps in 4 quadrants of the matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix Ps in each quadrant. The sum of all fingernails equals the total NAPSI score range is from 0 (no effect) to 80 (more severe psoriasis). LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, baseline cDMARD experience, visit, and treatment-by-visit interaction.
Time frame: Baseline, Week 24
Change From Baseline in Leeds Dactylitis Index-Basic (LDI-B)
The LDI-B measures the severity of dactylitis. In each digit, the ratio of the circumference of the affected digit to the circumference of the digit on the opposite hand or foot measured in mm. Each dactylitic digit was defined by a minimum increase of 10% in circumference over the contra-lateral digit. If the same digits on each hand or foot were thought to be involved, the clinician referred to a table of normative values for a value which was used to provide the comparison. The calculated ratio was multiplied by a tenderness score of 0 (not tender) or 1 (tender). Tenderness was assessed in the area between the joints. The results of each digit were then added to produce a total score. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, baseline cDMARD experience, visit, and treatment-by-visit interaction.
Time frame: Baseline, Week 24
Change From Baseline in in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
The BASDAI is a self-administered measure used to answer 6 questions with a 0 to 10 centimeter (cm) VAS pertaining to the 5 major symptoms of axial activity. To give each symptom equal weighting, the mean of the 2 scores relating to morning stiffness was taken. The resulting 0 to 50 score was divided by 5 to give a final 0 to 10 BASDAI Score. BASDAI ranges from 0-10. Higher scores represent greater disease activity. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, baseline cDMARD experience, visit, and treatment-by-visit interaction.
Time frame: Baseline, Week 24
Number of Participants With Treatment Emergent Anti-Ixekizumab Antibodies (TE-ADA) and Neutralizing Antibodies (NAb)
Number of participants with positive treatment emergent anti-ixekizumab antibodies and NAb was summarized by treatment group.
Time frame: Baseline to Week 24
Percent Change in American College of Rheumatology-N (ACR-N) Score
The ACR-N score is a continuous measure of clinical, laboratory, and functional outcomes that characterizes the percentage of improvement from baseline in disease activity and the lowest of either a) the percent change in tender joint count (TJC) b) the percent change in swollen joint count (SJC), or c) the median percent change of the remaining 5 ACR core criteria. An ACR-N score of X has improvement of at least X% in both TJC and SJC and a median improvement of at least X% in 5 criteria: patient's assessment of arthritis pain, PatGA, PGA, HAQ-DI and hs-CRP. ACR-N is calculated by allowing for negative results which indicate worsening. LS mean was calculated using Mixed Model Repeated Measurements (MMRM) analysis with treatment, baseline, geographic region, baseline conventional disease modifying anti-rheumatic drugs (cDMARD) experience, visit, and treatment.
Time frame: Baseline, 24 Weeks
Change From Baseline in Tender Joint Counts (TJC)
TJC is calculated based on tenderness response of 68 joints. TJC possible values range from 0 to 68. A lower TJC indicated less joint tenderness. A higher TJC indicated more joint tenderness. TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. LS mean was calculated using Mixed Model Repeated Measurements (MMRM) analysis with treatment, baseline, geographic region, baseline conventional disease modifying anti-rheumatic drugs (cDMARD) experience, visit, and treatment-by-visit interaction.
Time frame: Baseline, Week 24
Change From Baseline in Swollen Joint Counts (SJC)
SJC is calculated based on swelling response of 66 joints. SJC possible values range from 0 to 66. A lower SJC indicated less joint swelling. A higher SJC indicated more joint swelling. SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. LS mean was calculated using Mixed Model Repeated Measurements (MMRM) analysis with treatment, baseline, geographic region, baseline conventional disease modifying anti-rheumatic drugs (cDMARD) experience, visit, and treatment-by-visit interaction.
Time frame: Baseline, Week 24
Change From Baseline in Patient's Assessment of Pain VAS
The VAS is an instrument used to measure a person's subjective quantitative evaluation of an item such as pain intensity. The VAS contains a continuous line between two end points whereby the respondent places a mark on the line to indicate his or her response. In this study, participants scored their pain intensity in the most affected joint of the gout flare on a 0 100 mm VAS. The scale ranged from 0 (no pain) to 100 (unbearable pain). The scores were measured to the nearest millimeter from the left. LS mean was calculated using Mixed Model Repeated Measurements (MMRM) analysis with treatment, baseline, geographic region, baseline conventional disease modifying anti-rheumatic drugs (cDMARD) experience, visit, and treatment-by-visit interaction.
Time frame: Baseline, Week 24
Change From Baseline in Patient's Global Assessment of Disease Severity (PatGA) VAS
Participants scored their overall assessment of their PsA activity on a 0 to 100 mm horizontal VAS. The scale ranged from 0 (no disease activity) to 100 (extremely active disease activity). The scores were measured to the nearest millimeter from the left. LS mean was calculated using Mixed Model Repeated Measurements (MMRM) analysis with treatment, baseline, geographic region, baseline conventional disease modifying anti-rheumatic drugs (cDMARD) experience, visit, and treatment-by-visit interaction.
Time frame: Baseline, Week 24
Change From Baseline in Physician's Global Assessment of Disease Activity VAS
The investigator was asked to give an overall assessment of the severity of the participant's current PsA activity using a 0 to 100 mm horizontal VAS. The scale ranged from 0 no disease activity to 100 extremely active disease activity. The scores were measured to the nearest millimeter from the left. Least Square (LS) mean was calculated using Mixed Model Repeated Measurements (MMRM) analysis with treatment, baseline, geographic region, baseline conventional disease modifying anti-rheumatic drugs (cDMARD) experience, visit, and treatment-by-visit interaction.
Time frame: Baseline, 24 Weeks
Change From Baseline in C-Reactive Protein (CRP)
CRP milligram/liter (mg/L) was measured with a high sensitivity assay at a central laboratory to assess acute phase reactant. LS mean was calculated using Mixed Model Repeated Measurements (MMRM) analysis with treatment, baseline, geographic region, baseline conventional disease modifying anti-rheumatic drugs (cDMARD) experience, visit, and treatment-by-visit interaction.
Time frame: Baseline, Week 24
Change From Baseline in Leeds Enthesitis Index (LEI)
The LEI was developed specifically for use in PsA. It measures enthesitis at 6 sites (lateral epicondyle, left and right; medial femoral condyle, left and right; Achilles tendon insertion, left and right). Each site was assigned a score of 0 (absent) or 1 (present); the results from each site were then added to produce a total score (range 0 to 6). LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, baseline cDMARD experience, visit, treatment by visit interaction.
Time frame: Baseline, Week 24
Percentage of Participants Achieving Psoriasis Area and Severity Index 75%, 90%, 100% (PASI 75, 90, 100)
The PASI is an index that combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 were defined as having an improvement of at least 75% in the PASI compared to their baseline measures. Participants achieving PASI 90 were defined as having an improvement of ≥90% in the PASI score compared to baseline. Participants achieving PASI 100 were defined as having an improvement of 100% in the PASI score compared to baseline.
Time frame: Week 24
Change From Baseline in Itching Severity Using the Itch NRS
The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from psoriasis was indicated by circling the number that best described the worst level of itching in the past 24 hours. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, baseline cDMARD experience, visit, and treatment-by-visit interaction.
Time frame: Baseline, Week 24
| Milestone | Placebo (PBO) | Adalimumab (ADA) Q2W | Ixe Q4W | Ixe Q2W | Inadequate Responders (IR)/Ixe Q4W | IR/Ixe Q2W | IR PBO Washout | PBO Washout | Ixe Q4W/Ixe Q4W | Ixe Q2W/Ixe Q2W | Placebo Post-Treatment Follow-up Period | Adalimumab Post-Treatment Follow-up Period | Ixekizumab 80mg Q4W Post-Treatment Follow-up Period | Ixekizumab 80mg Q2W Post-Treatment Follow-up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 106 | 101 | 107 | 103 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received at least 1 dose of study drug | 106 | 101 | 107 | 102 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Classified as inadequate responder (ir) | 27 | 9 | 11 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 91 | 97 | 97 | 96 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 15 | 4 | 10 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Entry criteria not met | 1 | 1 | 3 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 2 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 4 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 3 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo (PBO) | Adalimumab (ADA) Q2W | Ixe Q4W | Ixe Q2W | Inadequate Responders (IR)/Ixe Q4W | IR/Ixe Q2W | IR PBO Washout | PBO Washout | Ixe Q4W/Ixe Q4W | Ixe Q2W/Ixe Q2W | Placebo Post-Treatment Follow-up Period | Adalimumab Post-Treatment Follow-up Period | Ixekizumab 80mg Q4W Post-Treatment Follow-up Period | Ixekizumab 80mg Q2W Post-Treatment Follow-up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 24 | 24 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 24 | 24 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo (PBO) | Adalimumab (ADA) Q2W | Ixe Q4W | Ixe Q2W | Inadequate Responders (IR)/Ixe Q4W | IR/Ixe Q2W | IR PBO Washout | PBO Washout | Ixe Q4W/Ixe Q4W | Ixe Q2W/Ixe Q2W | Placebo Post-Treatment Follow-up Period | Adalimumab Post-Treatment Follow-up Period | Ixekizumab 80mg Q4W Post-Treatment Follow-up Period | Ixekizumab 80mg Q2W Post-Treatment Follow-up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 88 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 77 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Entry criteria not met | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo (PBO) | Adalimumab (ADA) Q2W | Ixe Q4W | Ixe Q2W | Inadequate Responders (IR)/Ixe Q4W | IR/Ixe Q2W | IR PBO Washout | PBO Washout | Ixe Q4W/Ixe Q4W | Ixe Q2W/Ixe Q2W | Placebo Post-Treatment Follow-up Period | Adalimumab Post-Treatment Follow-up Period | Ixekizumab 80mg Q4W Post-Treatment Follow-up Period | Ixekizumab 80mg Q2W Post-Treatment Follow-up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 187 | 183 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 121 | 122 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 66 | 61 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 37 | 31 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 21 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 7 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo (PBO) | Adalimumab (ADA) Q2W | Ixe Q4W | Ixe Q2W | Inadequate Responders (IR)/Ixe Q4W | IR/Ixe Q2W | IR PBO Washout | PBO Washout | Ixe Q4W/Ixe Q4W | Ixe Q2W/Ixe Q2W | Placebo Post-Treatment Follow-up Period | Adalimumab Post-Treatment Follow-up Period | Ixekizumab 80mg Q4W Post-Treatment Follow-up Period | Ixekizumab 80mg Q2W Post-Treatment Follow-up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20 | 1 | 165 | 171 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20 | 0 | 156 | 166 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 9 | 5 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
ACR20 response is defined as a ≥20% improvement from baseline for tender joint count (TJC) and swollen joint count (SJC) and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain visual analog scale (VAS), Participant's Global Assessment of Disease Activity VAS (PatGA), Physician's Global Assessment of the Disease Activity VAS (PGA), Participant's Assessment of Physical Function using the Health Assessment Questionnaire Disability Index (HAQ-DI), or Acute Phase Reactant as measured by high sensitivity C-reactive protein (hs-CRP).
| percentage of participants | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response at Week 24 (Efficacy of Ixekizumab in Participants With Active Psoriatic Arthritis. Measure: American College of Rheumatology 20 Index [ACR20]) | 30.2 | 57.4 | 57.9 | 62.1 |
ACR20 response is defined as a ≥20% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.
| percentage of participants | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| Percentage of Participants Achieving ACR20 Response | 31.1 | 51.5 | 57.0 | 60.2 |
ACR50 response is defined as a ≥50% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.
| percentage of participants | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 50 (ACR50) Response | 15.1 | 38.6 | 40.2 | 46.6 |
ACR70 response is defined as a ≥70% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.
| percentage of participants | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 70 (ACR70) Score | 5.7 | 25.7 | 23.4 | 34.0 |
HAQ-DI is a participant reported questionnaire that measures disease-associated disability (physical function). It consists of 24 questions with 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other daily activities. The disability section scores the participant's self-perception on the degree of difficulty (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do), covering the 8 domains. The HAQ-DI is a composite ranging from 0-3 with lower scores indicating less functional disability. The reported use of special aids or devices and/or the need for assistance of another person to perform these activities is assessed. Least Square (LS) mean was calculated using Mixed Model Repeated Measurements (MMRM) analysis with treatment, baseline score, geographic region, baseline conventional disease modifying anti-rheumatic drugs (cDMARD) experience, visit, and treatment-by-visit interaction.
| units on a scale | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Scores (Quality of Life and Outcome Assessments Measures: Participant Reported Outcomes [PRO]) | -0.1797 ± 0.0524 | -0.3712 ± 0.0510 | -0.4431 ± 0.0503 | -0.4963 ± 0.0507 |
The mTSS measures the extent of bone erosions (20 joints per hand and 12 joints per foot) and joint space narrowing (20 joints per hand and 6 joints per foot), with higher scores representing greater damage. An increase from baseline represents disease progression and / or joint worsening. Scores range from 0-528. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, and baseline cDMARD experience, visit, treatment by visit interaction.
| units on a scale | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| Change From Baseline in Modified Total Sharp Score (mTSS) (Efficacy of Ixekizumab in Participants With Active Psoriatic Arthritis. Measure: Modified Total Sharp Score [mTSS]) | 0.49 ± 0.086 | 0.10 ± 0.085 | 0.17 ± 0.082 | 0.08 ± 0.083 |
The PASI is an index that combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 were defined as having an improvement of at least 75% in the PASI compared to their baseline measures. Participants achieving PASI 90 were defined as having an improvement of ≥90% in the PASI score compared to baseline. Participants achieving PASI 100 were defined as having an improvement of 100% in the PASI score compared to baseline.
| percentage of participants | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| PASI 75 | 7.5 | 33.8 | 75.3 | 69.5 |
| PASI 90 | 1.5 | 22.1 | 52.1 | 57.6 |
| PASI 100 | 1.5 | 14.7 | 31.5 | 40.7 |
The LEI was developed specifically for use in PsA. It measures enthesitis at 6 sites (lateral epicondyle, left and right; medial femoral condyle, left and right; Achilles tendon insertion, left and right). Each site was assigned a score of 0 (absent) or 1 (present); the results from each site were then added to produce a total score (range 0 to 6). LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, baseline cDMARD experience, visit, treatment by visit interaction.
| units on a scale | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| Change From Baseline in Leeds Enthesitis Index (LEI) | -0.8 ± 0.24 | -0.8 ± 0.24 | -0.9 ± 0.21 | -1.5 ± 0.24 |
The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from psoriasis was indicated by circling the number that best described the worst level of itching in the past 24 hours. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, baseline cDMARD experience, visit, and treatment-by-visit interaction.
| units on a scale | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| Change From Baseline in Itching Severity Using the Itch Numeric Rating Scale (NRS) (Quality of Life and Outcome Assessments Measures: Participant Reported Outcomes [PRO]) | 0.2 ± 0.27 | -1.4 ± 0.28 | -2.6 ± 0.27 | -2.8 ± 0.30 |
The Fatigue Severity NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine." Participants rated their fatigue (feeling tired or worn out) by circling the 1 number that described their worst level of fatigue during the past 24 hours. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, baseline cDMARD experience, visit, and treatment-by-visit interaction.
| units on a scale | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| Change From Baseline in Fatigue Severity NRS Score (Quality of Life and Outcome Assessments Measures: Participant Reported Outcomes [PRO]) | -1.3 ± 0.25 | -1.5 ± 0.24 | -1.6 ± 0.24 | -1.9 ± 0.24 |
JSN score (a component of the modified Total Sharp Score \[mTSS\]) measures the extent of joint space narrowing in peripheral joints. JSN (20 joints per hand and 6 joints per foot), with higher scores representing greater damage. JSN score range is 0 (no narrowing) to 208 (high narrowing). Increase from baseline represents disease progression and / or joint worsening. BES (a component of the \[mTSS\]) measures the extent of bone erosion in peripheral joints. BES measures the extent of joint erosions (20 joints per hand and 12 joints per foot), with higher scores representing greater damage. Erosion score range is from 0 (no erosion) to 320 (high erosion). LS mean was calculated using linear extrapolation for ANCOVA analysis with treatment, baseline score, geographic region, and baseline cDMARD experience.
| units on a scale | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| Joint Space Narrowing Score | 0.07 ± 0.031 | 0.01 ± 0.031 | 0.04 ± 0.030 | 0.01 ± 0.030 |
| Bone Erosion Score | 0.44 ± 0.077 | 0.12 ± 0.077 | 0.15 ± 0.075 | 0.08 ± 0.075 |
SF-36 is a standardized participant-administered measure designed to evaluate 8 domains of functional health and well being: physical and social functioning, physical and emotional role (role-physical, role-emotional) limitations, bodily pain, general health, vitality, mental health with 2 components (physical component score \[PCS\] and mental component score \[MCS\]). The PCS and MCS scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, baseline cDMARD experience, visit, and treatment-by-visit interaction.
| units on a scale | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| PCS Score | 2.94 ± 0.958 | 6.78 ± 0.904 | 7.45 ± 0.894 | 8.24 ± 0.898 |
| MCS Score | 2.67 ± 1.013 | 4.22 ± 0.943 | 4.86 ± 0.933 | 3.39 ± 0.936 |
The QIDS-SR16 is a self-administered 16-item instrument intended to assess the existence and severity of symptoms of depression. A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. Each item scaled from 0 (no symptoms) to 3 (all symptoms). The 16 items corresponding to 9 depression domains are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, baseline cDMARD experience, visit, and treatment-by-visit interaction.
| units on a scale | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Reported 16 Items (QIDS-SR16) (Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes [PRO]) | -0.9 ± 0.36 | -1.6 ± 0.33 | -0.8 ± 0.32 | -0.7 ± 0.32 |
The DAS28-CRP is a measure of disease activity in 28 joints that consists of a composite numerical score with the following variables: TJC28, SJC28, hs-CRP measured in milligram/liter (mg/L), and Participant's Global Assessment of Disease Activity recorded by participants on a 0 to 100 millimeter (mm) VAS. For DAS28-CRP, the Tender Joint Count 28 (TJC28) and Swollen Joint Count (SJC28) are a subset of TJC and SJC, and include 14 joints on each side of the body: 2 shoulders, 2 elbows, 2 wrists, 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. DAS28 values range from 0 to 9.4. Higher values indicate more severe symptoms and greater functional impairment. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, baseline cDMARD experience, visit, and treatment-by-visit.
| units on a scale | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| Change From Baseline in Disease Activity Score (28 Diarthrodial Joint Count) Based on C-ReactiveProtein (DAS28-CRP) Measure: Non-Arthritic Disease | -0.835 ± 0.1307 | -1.743 ± 0.1215 | -1.955 ± 0.1206 | -2.036 ± 0.1225 |
The PsARC is a composite criteria reported in terms of the percentage of participants achieving response according to the following criterion: TJC, SJC, PGA, and PatGA. Overall response is defined by improvement from baseline assessment in 2 of 4 criteria, 1 of which must be a joint count; there must not be worsening in any of the 4 criteria: at least 30% reduction in TJC, at least 30% reduction in SJC, at least a 20 millimeter (mm) reduction in PGA and at least a 20 mm reduction in PatGA which is equivalent to 20 mm reduction. The results from the 2 VAS measures were assessed as a difference from baseline in mm.
| percentage of participants | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| Percentage of Participants Meeting the Psoriatic Arthritis Response Criteria (PsARC Modified) | 32.1 | 58.4 | 57.9 | 66.0 |
The sPGA is the physician's determination of the severity of the participant's psoriasis lesions overall at a given time point. Overall lesions were categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's psoriasis was assessed at a given time point on in which 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, 5 = very severe.
| percentage of participants | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| Percentage of Participants Achieving Static Physician Global Assessment (sPGA) of 0 or 1 and With at Least a 2-point Improvement From Baseline | 17.1 | 62.2 | 65.4 | 73.2 |
The investigator evaluated the percentage involvement of psoriasis on each participant's BSA on a continuous scale from 0% = no involvement to 100% = full involvement, where 1% corresponded to the size of the participant's handprint including the palm, fingers, and thumb. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, baseline cDMARD experience, visit, and treatment-by-visit interaction.
| percent change in BSA | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| Percent Change From Baseline in Body Surface Area (BSA) | -2.7 ± 1.36 | -9.5 ± 1.35 | -12.0 ± 1.32 | -10.6 ± 1.39 |
The NAPSI scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps by area of involvement. The fingernail is divided into quadrants. Each fingernail is given a score for fingernail bed Ps 0 (none) to 4 (Ps in 4 quadrants of the fingernail) and fingernail matrix Ps 0 (none) to 4 (Ps in 4 quadrants of the matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix Ps in each quadrant. The sum of all fingernails equals the total NAPSI score range is from 0 (no effect) to 80 (more severe psoriasis). LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, baseline cDMARD experience, visit, and treatment-by-visit interaction.
| units on a scale | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| Change From Baseline in the Nail Psoriasis Severity Index (NAPSI) Score Fingernail Involvement at Baseline | -2.4 ± 1.66 | -10.7 ± 1.49 | -14.0 ± 1.54 | -15.5 ± 1.49 |
The LDI-B measures the severity of dactylitis. In each digit, the ratio of the circumference of the affected digit to the circumference of the digit on the opposite hand or foot measured in mm. Each dactylitic digit was defined by a minimum increase of 10% in circumference over the contra-lateral digit. If the same digits on each hand or foot were thought to be involved, the clinician referred to a table of normative values for a value which was used to provide the comparison. The calculated ratio was multiplied by a tenderness score of 0 (not tender) or 1 (tender). Tenderness was assessed in the area between the joints. The results of each digit were then added to produce a total score. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, baseline cDMARD experience, visit, and treatment-by-visit interaction.
| units on a scale | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| Change From Baseline in Leeds Dactylitis Index-Basic (LDI-B) | -25.4 ± 6.53 | -57.1 ± 7.84 | -57.1 ± 5.67 | -48.3 ± 6.31 |
The BASDAI is a self-administered measure used to answer 6 questions with a 0 to 10 centimeter (cm) VAS pertaining to the 5 major symptoms of axial activity. To give each symptom equal weighting, the mean of the 2 scores relating to morning stiffness was taken. The resulting 0 to 50 score was divided by 5 to give a final 0 to 10 BASDAI Score. BASDAI ranges from 0-10. Higher scores represent greater disease activity. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, baseline cDMARD experience, visit, and treatment-by-visit interaction.
| units on a scale | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| Change From Baseline in in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) | -1.25 ± 0.268 | -2.42 ± 0.249 | -2.74 ± 0.234 | -2.91 ± 0.251 |
Number of participants with positive treatment emergent anti-ixekizumab antibodies and NAb was summarized by treatment group.
| participants | Placebo | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|
| Treatment Emergent (TE) | 0 | 6 | 5 |
| NAb | 0 | 0 | 0 |
The ACR-N score is a continuous measure of clinical, laboratory, and functional outcomes that characterizes the percentage of improvement from baseline in disease activity and the lowest of either a) the percent change in tender joint count (TJC) b) the percent change in swollen joint count (SJC), or c) the median percent change of the remaining 5 ACR core criteria. An ACR-N score of X has improvement of at least X% in both TJC and SJC and a median improvement of at least X% in 5 criteria: patient's assessment of arthritis pain, PatGA, PGA, HAQ-DI and hs-CRP. ACR-N is calculated by allowing for negative results which indicate worsening. LS mean was calculated using Mixed Model Repeated Measurements (MMRM) analysis with treatment, baseline, geographic region, baseline conventional disease modifying anti-rheumatic drugs (cDMARD) experience, visit, and treatment.
| percent change | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| Percent Change in American College of Rheumatology-N (ACR-N) Score | -4.182 ± 6.1417 | 28.517 ± 5.9189 | 33.509 ± 5.8905 | 30.391 ± 5.9736 |
TJC is calculated based on tenderness response of 68 joints. TJC possible values range from 0 to 68. A lower TJC indicated less joint tenderness. A higher TJC indicated more joint tenderness. TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. LS mean was calculated using Mixed Model Repeated Measurements (MMRM) analysis with treatment, baseline, geographic region, baseline conventional disease modifying anti-rheumatic drugs (cDMARD) experience, visit, and treatment-by-visit interaction.
| joint counts | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| Change From Baseline in Tender Joint Counts (TJC) | -4.7 ± 1.14 | -10.1 ± 1.10 | -11.9 ± 1.08 | -13.6 ± 1.09 |
SJC is calculated based on swelling response of 66 joints. SJC possible values range from 0 to 66. A lower SJC indicated less joint swelling. A higher SJC indicated more joint swelling. SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. LS mean was calculated using Mixed Model Repeated Measurements (MMRM) analysis with treatment, baseline, geographic region, baseline conventional disease modifying anti-rheumatic drugs (cDMARD) experience, visit, and treatment-by-visit interaction.
| joint counts | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| Change From Baseline in Swollen Joint Counts (SJC) | -3.5 ± 0.62 | -6.1 ± 0.59 | -7.0 ± 0.59 | -8.3 ± 0.59 |
The VAS is an instrument used to measure a person's subjective quantitative evaluation of an item such as pain intensity. The VAS contains a continuous line between two end points whereby the respondent places a mark on the line to indicate his or her response. In this study, participants scored their pain intensity in the most affected joint of the gout flare on a 0 100 mm VAS. The scale ranged from 0 (no pain) to 100 (unbearable pain). The scores were measured to the nearest millimeter from the left. LS mean was calculated using Mixed Model Repeated Measurements (MMRM) analysis with treatment, baseline, geographic region, baseline conventional disease modifying anti-rheumatic drugs (cDMARD) experience, visit, and treatment-by-visit interaction.
| units on a scale | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| Change From Baseline in Patient's Assessment of Pain VAS | -14.0 ± 2.68 | -30.0 ± 2.52 | -29.6 ± 2.51 | -31.6 ± 2.54 |
Participants scored their overall assessment of their PsA activity on a 0 to 100 mm horizontal VAS. The scale ranged from 0 (no disease activity) to 100 (extremely active disease activity). The scores were measured to the nearest millimeter from the left. LS mean was calculated using Mixed Model Repeated Measurements (MMRM) analysis with treatment, baseline, geographic region, baseline conventional disease modifying anti-rheumatic drugs (cDMARD) experience, visit, and treatment-by-visit interaction.
| units on a scale | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| Change From Baseline in Patient's Global Assessment of Disease Severity (PatGA) VAS | -14.8 ± 2.65 | -31.6 ± 2.49 | -33.8 ± 2.48 | -35.6 ± 2.50 |
The investigator was asked to give an overall assessment of the severity of the participant's current PsA activity using a 0 to 100 mm horizontal VAS. The scale ranged from 0 no disease activity to 100 extremely active disease activity. The scores were measured to the nearest millimeter from the left. Least Square (LS) mean was calculated using Mixed Model Repeated Measurements (MMRM) analysis with treatment, baseline, geographic region, baseline conventional disease modifying anti-rheumatic drugs (cDMARD) experience, visit, and treatment-by-visit interaction.
| units on a scale | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| Change From Baseline in Physician's Global Assessment of Disease Activity VAS | -24.2 ± 2.14 | -34.7 ± 2.10 | -38.5 ± 2.06 | -42.0 ± 1.99 |
CRP milligram/liter (mg/L) was measured with a high sensitivity assay at a central laboratory to assess acute phase reactant. LS mean was calculated using Mixed Model Repeated Measurements (MMRM) analysis with treatment, baseline, geographic region, baseline conventional disease modifying anti-rheumatic drugs (cDMARD) experience, visit, and treatment-by-visit interaction.
| milligram/liter (mg/L) | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| Change From Baseline in C-Reactive Protein (CRP) | -3.873 ± 1.4292 | -7.512 ± 1.2674 | -8.804 ± 1.2602 | -8.942 ± 1.2552 |
The LEI was developed specifically for use in PsA. It measures enthesitis at 6 sites (lateral epicondyle, left and right; medial femoral condyle, left and right; Achilles tendon insertion, left and right). Each site was assigned a score of 0 (absent) or 1 (present); the results from each site were then added to produce a total score (range 0 to 6). LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, baseline cDMARD experience, visit, treatment by visit interaction.
| units on a scale | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| Change From Baseline in Leeds Enthesitis Index (LEI) | -0.8 ± 0.26 | -0.9 ± 0.23 | -1.3 ± 0.21 | -1.4 ± 0.24 |
The PASI is an index that combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 were defined as having an improvement of at least 75% in the PASI compared to their baseline measures. Participants achieving PASI 90 were defined as having an improvement of ≥90% in the PASI score compared to baseline. Participants achieving PASI 100 were defined as having an improvement of 100% in the PASI score compared to baseline.
| percentage of participants | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| PASI 75 | 10.9 | 55.2 | 71.2 | 80.4 |
| PASI 90 | 6.3 | 37.3 | 56.2 | 67.9 |
| PASI 100 | 3.1 | 23.9 | 42.5 | 53.6 |
The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from psoriasis was indicated by circling the number that best described the worst level of itching in the past 24 hours. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, baseline cDMARD experience, visit, and treatment-by-visit interaction.
| units on a scale | Placebo | Adalimumab Q2W | Ixekizumab Q4W | Ixekizumab Q2W |
|---|---|---|---|---|
| Change From Baseline in Itching Severity Using the Itch NRS | -0.3 ± 0.32 | -1.7 ± 0.29 | -2.9 ± 0.29 | -2.8 ± 0.31 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (PBO) Double-Blind Period | — | 2/106 (1.9%) | 16/106 (15.1%) |
| Adalimumab (ADA) Double-Blind Period | — | 5/101 (5%) | 18/101 (17.8%) |
| Ixe Q2W Double-Blind Period | — | 6/107 (5.6%) | 33/107 (30.8%) |
| Ixe Q4W Double-Blind Period | — | 3/102 (2.9%) | 31/102 (30.4%) |
| IR IXE Q4W | — | 0/24 (0%) | 0/24 (0%) |
| IR IXE Q2W | — | 0/24 (0%) | 0/24 (0%) |
| IR PBO Washout | — | 0/9 (0%) | 0/9 (0%) |
| PBO Washout | — | 1/88 (1.1%) | 7/88 (8%) |
| IXE Q4W | — | 28/187 (15%) | 62/187 (33.2%) |
| IXE Q2W | — | 19/183 (10.4%) | 66/183 (36.1%) |
| PBO Post-Treatment Follow-Up Period | — | 0/20 (0%) | 0/20 (0%) |
| Adalimumab Post-Treatment Follow-up Period | — | 0/1 (0%) | 0/1 (0%) |
| IXE Q4W Post-Treatment Follow-up Period | — | 2/165 (1.2%) | 0/165 (0%) |
| IXE Q2W Post-Treatment Follow-up Period | — | 2/171 (1.2%) | 0/171 (0%) |
| Event | Placebo (PBO) Double-Blind Period | Adalimumab (ADA) Double-Blind Period | Ixe Q2W Double-Blind Period | Ixe Q4W Double-Blind Period | IR IXE Q4W | IR IXE Q2W | IR PBO Washout | PBO Washout | IXE Q4W | IXE Q2W | PBO Post-Treatment Follow-Up Period | Adalimumab Post-Treatment Follow-up Period | IXE Q4W Post-Treatment Follow-up Period | IXE Q2W Post-Treatment Follow-up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MetrorrhagiaReproductive system and breast disorders | 0/58 | 1/50 | 0/62 | 0/55 | 0/16 | 0/16 | 0/8 | 0/38 | 0/109 | 0/91 | 0/10 | 0/1 | 0/94 | 0/84 |
| Bartholin's cystReproductive system and breast disorders | 1/58 | 0/50 | 0/62 | 0/55 | 0/16 | 0/16 | 0/8 | 0/38 | 0/109 | 0/91 | 0/10 | 0/1 | 0/94 | 0/84 |
| Uterine polypReproductive system and breast disorders | 0/58 | 0/50 | 1/62 | 0/55 | 0/16 | 0/16 | 0/8 | 0/38 | 0/109 | 0/91 | 0/10 | 0/1 | 0/94 | 0/84 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/48 | 0/51 | 0/45 | 0/47 | 0/8 | 0/8 | 0/1 | 0/50 | 0/78 | 0/92 | 0/10 | 0/1 | 0/71 | 1/87 |
| HypertensionVascular disorders | 0/106 | 0/101 | 0/107 | 0/102 | 0/24 | 0/24 | 0/9 | 1/88 | 0/187 | 1/183 | 0/20 | 0/1 | 0/165 | 0/171 |
| Coronary artery diseaseCardiac disorders | 0/106 | 0/101 | 0/107 | 0/102 | 0/24 | 0/24 | 0/9 | 0/88 | 0/187 | 2/183 | 0/20 | 0/1 | 0/165 | 0/171 |
| Cholecystitis acuteHepatobiliary disorders | 0/106 | 0/101 | 0/107 | 0/102 | 0/24 | 0/24 | 0/9 | 0/88 | 2/187 | 0/183 | 0/20 | 0/1 | 0/165 | 0/171 |
| PneumoniaInfections and infestations | 0/106 | 0/101 | 0/107 | 0/102 | 0/24 | 0/24 | 0/9 | 0/88 | 2/187 | 0/183 | 0/20 | 0/1 | 0/165 | 0/171 |
| Gastric ulcerGastrointestinal disorders | 0/106 | 1/101 | 0/107 | 0/102 | 0/24 | 0/24 | 0/9 | 0/88 | 1/187 | 0/183 | 0/20 | 0/1 | 0/165 | 0/171 |
| OesophagitisGastrointestinal disorders | 0/106 | 1/101 | 0/107 | 0/102 | 0/24 | 0/24 | 0/9 | 0/88 | 0/187 | 0/183 | 0/20 | 0/1 | 0/165 | 0/171 |
| Event | Placebo (PBO) Double-Blind Period | Adalimumab (ADA) Double-Blind Period | Ixe Q2W Double-Blind Period | Ixe Q4W Double-Blind Period | IR IXE Q4W | IR IXE Q2W | IR PBO Washout | PBO Washout | IXE Q4W | IXE Q2W | PBO Post-Treatment Follow-Up Period | Adalimumab Post-Treatment Follow-up Period | IXE Q4W Post-Treatment Follow-up Period | IXE Q2W Post-Treatment Follow-up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Injection site reactionGeneral disorders | 0/106 | 3/101 | 13/107 | 16/102 | 0/24 | 0/24 | 0/9 | 0/88 | 12/187 | 13/183 | 0/20 | 0/1 | 0/165 | 0/171 |
| Injection site erythemaGeneral disorders | 0/106 | 2/101 | 7/107 | 13/102 | 0/24 | 0/24 | 0/9 | 0/88 | 3/187 | 5/183 | 0/20 | 0/1 | 0/165 | 0/171 |
| Viral upper respiratory tract infectionInfections and infestations | 5/106 | 6/101 | 6/107 | 2/102 | 0/24 | 0/24 | 0/9 | 3/88 | 21/187 | 21/183 | 0/20 | 0/1 | 0/165 | 0/171 |
| Upper respiratory tract infectionInfections and infestations | 7/106 | 5/101 | 5/107 | 3/102 | 0/24 | 0/24 | 0/9 | 2/88 | 21/187 | 18/183 | 0/20 | 0/1 | 0/165 | 0/171 |
| PharyngitisInfections and infestations | 1/106 | 0/101 | 1/107 | 2/102 | 0/24 | 0/24 | 0/9 | 2/88 | 5/187 | 12/183 | 0/20 | 0/1 | 0/165 | 0/171 |
| Back painMusculoskeletal and connective tissue disorders | 0/106 | 3/101 | 2/107 | 2/102 | 0/24 | 0/24 | 0/9 | 0/88 | 11/187 | 6/183 | 0/20 | 0/1 | 0/165 | 0/171 |
| BronchitisInfections and infestations | 3/106 | 4/101 | 3/107 | 3/102 | 0/24 | 0/24 | 0/9 | 0/88 | 10/187 | 10/183 | 0/20 | 0/1 | 0/165 | 0/171 |
All randomized participants
| Age, Continuous(years) | Placebo | ADA Q2W | Ixe Q4W | Ixe Q2W | Total |
|---|---|---|---|---|---|
| Mean | 50.60 ± 12.32 | 48.58 ± 12.43 | 49.07 ± 10.07 | 49.79 ± 12.62 | 49.52 ± 11.87 |
| Sex: Female, Male(Participants) | Placebo | ADA Q2W | Ixe Q4W | Ixe Q2W | Total |
|---|---|---|---|---|---|
| Female | 58 | 50 | 62 | 55 | 225 |
| Male | 48 | 51 | 45 | 48 | 192 |
| Race (NIH/OMB)(Participants) | Placebo | ADA Q2W | Ixe Q4W | Ixe Q2W | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 3 | 2 | 2 | 9 |
| Asian | 5 | 3 | 2 | 5 | 15 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 99 | 95 | 102 | 96 | 392 |
| More than one race | 0 | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | ADA Q2W | Ixe Q4W | Ixe Q2W | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 5 | 5 | 4 | 20 |
| Not Hispanic or Latino | 92 | 83 | 94 | 87 | 356 |
| Unknown or Not Reported | 8 | 13 | 8 | 12 | 41 |
| Region of Enrollment(Participants) | Placebo | ADA Q2W | Ixe Q4W | Ixe Q2W | Total |
|---|---|---|---|---|---|
| Russia | 9 | 7 | 10 | 8 | 34 |
| United States | 22 | 21 | 20 | 20 | 83 |
| Japan | 4 | 2 | 2 | 4 | 12 |
| Ukraine | 9 | 7 | 9 | 10 | 35 |
| United Kingdom | 3 | 5 | 5 | 4 | 17 |
| Spain | 4 | 2 | 3 | 4 | 13 |
| Canada | 1 | 1 | 2 | 0 | 4 |
| Czechia | 22 | 25 | 23 | 22 | 92 |
| Netherlands | 1 | 0 | 1 | 0 | 2 |
| Belgium | 2 | 2 | 0 | 1 | 5 |
| Poland | 16 | 14 | 15 | 15 | 60 |
| Mexico | 3 | 4 | 3 | 2 | 12 |
| France | 1 | 0 | 1 | 1 | 3 |
| Bulgaria | 3 | 4 | 5 | 4 | 16 |
| Estonia | 6 | 7 | 8 | 8 | 29 |
Showing the first 100 of 116 sites across 15 countries. Choose a country and city above to see the rest.
The record gives a start of Dec 2012, a primary completion of Dec 2014 and a completion of Sep 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2016, 1 year 10 months after primary completion. A results delay was requested in Sep 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ixekizumab